Note de episod
Friday, November 13, 2026
The Future of Pharmacy: Clinical Innovation, Closures & a New Kind of Conference
Welcome to This Week in Pharmacy, where we bring you the headlines, innovations, and conversations shaping the future of pharmacy care.
Today's episode is sponsored by Independent Pharmacy Cooperative (IPC), supporting the strength and sustainability of independent community pharmacies, and Finch Marketing, helping pharmacy businesses communicate their value, strengthen their brands, and connect with their communities.
This week, we're covering major FDA safety developments, the continued disappearance of community pharmacies, a potentially transformative Medicare payment model, and two important new drug approvals.
Then we're joined by a true pioneer in functional pharmacy, Robert Kress, RPh, to discuss a new kind of pharmacy conference and why the future of the profession may depend on rethinking how pharmacists learn, collaborate, and practice.
Segment 1 — Vox Top 5 Pharmacy News
1. FDA Adds New GLP-1 Safety Warnings
The FDA is requiring updated labeling for GLP-1 receptor agonists, including medications used for diabetes and obesity, over a potential increased risk of a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION.
An FDA review of 126 clinical trials identified 6.4 cases per 100,000 patient-years among GLP-1 users versus 3.8 among comparator patients.
The condition can cause sudden, painless vision loss. Although the absolute risk is low, pharmacists must be prepared to counsel patients, recognize symptoms, and coordinate timely medical evaluation.
Source: FDA Drug Safety Communication
2. More Than 3,000 U.S. Pharmacies Disappear
New research published in the Journal of the American Pharmacists Association reveals that between 2022 and 2024:
7,240 community pharmacies closed.
4,178 new locations opened.
The country experienced a net loss of 3,062 pharmacies.
Chain pharmacies represented approximately 2,680 of those net losses, with independents accounting for 382.
Declining reimbursement, PBM practices, and changing retail economics continue to place tremendous pressure on pharmacy access.
Source: Drug Topics — Pharmacy Closures
3. Medicare ACCESS Model Opens New Clinical Opportunities
CMS's ACCESS Model represents an important shift toward outcome-based reimbursement for chronic disease management.
The program supports technology-enabled care for conditions including diabetes, hypertension, chronic pain, and behavioral health.
Participating organizations must meet Medicare enrollment, clinical oversight, and other program requirements. It is not automatic reimbursement for every pharmacist.
NCPA leadership sees potential opportunities for community pharmacies to participate in new clinical care delivery models.
Sources: CMS ACCESS Model | Drug Topics — NCPA Interview
4. FDA Approves First Factor XIa Inhibitor for Stroke Prevention
The FDA approved Sunharbo (asundexian), a new Factor XIa…
Site: pharmacypodcastnetwork.podbean.com

